Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTP0301 is a low-volume (1-liter) polyethylene glycol (PEG)-based bowel preparation solution developed by Taejoon Pharmaceutical. It consists of a combination of polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid. Designed to improve patient compliance by reducing the required intake volume compared to traditional 2-liter or 4-liter PEG solutions, CTP0301 functions as an osmotic laxative. The high concentration of PEG and sodium sulfate, along with the osmotic action of the ascorbate components, induces a purgative effect by retaining water in the intestinal lumen, effectively cleansing the colon in preparation for colonoscopy. CTP0301 has been evaluated in Phase 3 clinical trials, demonstrating non-inferiority in cleansing efficacy and improved patient preference compared to standard-volume preparations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cleanview-All.